Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03736616
Title Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Swedish Medical Center
Indications

relapsed/refractory diffuse large B-cell lymphoma

Therapies

Acalabrutinib

Carmustine + Cytarabine + Etoposide + Melphalan

Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Swedish Cancer Institute Recruiting Seattle Washington 98104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field